221 related articles for article (PubMed ID: 31837576)
41. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
Nakano K; Marshall S; Taira S; Sato Y; Tomomatsu J; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Kawabata K; Takahashi S
Oral Oncol; 2017 Oct; 73():21-26. PubMed ID: 28939072
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
43. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A; Toussaint P; Neidhardt EM; Paulus V; Saintigny P; Fayette J
Anticancer Drugs; 2017 Apr; 28(4):357-361. PubMed ID: 28166090
[TBL] [Abstract][Full Text] [Related]
45. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
46. Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Kua VF; Ismail F; Chee Ee Phua V; Aslan NM
Asian Pac J Cancer Prev; 2013; 14(2):1121-6. PubMed ID: 23621198
[TBL] [Abstract][Full Text] [Related]
47. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
48. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
[TBL] [Abstract][Full Text] [Related]
49. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
[TBL] [Abstract][Full Text] [Related]
50. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy for squamous cell carcinoma of the head and neck.
Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
[TBL] [Abstract][Full Text] [Related]
52. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
[TBL] [Abstract][Full Text] [Related]
53. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
54. Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Burgy M; Barthélémy P; Lefevre F; Dupret-Bories A; Truntzer P; Korenbaum C; Flesch H; Bronner G; Borel C
Oncology; 2017; 93(1):11-17. PubMed ID: 28423384
[TBL] [Abstract][Full Text] [Related]
55. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
Weiss JM; Bagley S; Hwang WT; Bauml J; Olson JG; Cohen RB; Hayes DN; Langer C
Cancer; 2016 Aug; 122(15):2350-5. PubMed ID: 27197056
[TBL] [Abstract][Full Text] [Related]
56. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
57. Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Szturz P; Specenier P; Van Laer C; Van Den Weyngaert D; Corthouts B; Carp L; Van Marck E; Vanderveken O; Vermorken JB
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1629-36. PubMed ID: 26044403
[TBL] [Abstract][Full Text] [Related]
58. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
59. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
60. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
